153 related articles for article (PubMed ID: 38249866)
1. Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study.
He X; Fang J; Yu P; Hu W; Zhang Q; Zhang Z; Zhou M; Wang X; Bian X
J Thorac Dis; 2023 Dec; 15(12):6687-6696. PubMed ID: 38249866
[TBL] [Abstract][Full Text] [Related]
2. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
3. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Ding Q; Liu Y; Ju H; Song H; Xiao Y; Liu X; Ren G; Wei D
Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e525-e529. PubMed ID: 37330963
[TBL] [Abstract][Full Text] [Related]
4. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.
Qu W; Wang F; Qin S; Sun Y; Huang C
Ther Adv Med Oncol; 2024; 16():17588359241242607. PubMed ID: 38606164
[TBL] [Abstract][Full Text] [Related]
5. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.
Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J
Front Oncol; 2023; 13():1280208. PubMed ID: 38090483
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
7. Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.
Hui-Mei P; Guang-Ming H; Xiao-Ling Q; Hong-Liang Z; Si-Jun W
Indian J Dermatol; 2023; 68(3):318-326. PubMed ID: 37529461
[TBL] [Abstract][Full Text] [Related]
8. Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.
Ma R; Wang JL; Wang YY
Exp Hematol Oncol; 2022 Oct; 11(1):78. PubMed ID: 36289520
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.
Song G; Zhang FF; Cheng HD
Australas J Dermatol; 2022 May; 63(2):217-221. PubMed ID: 35229882
[TBL] [Abstract][Full Text] [Related]
10. Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.
Yin L; Liu KC; Lv WF; Xu SB; Lu D; Zhou CZ; Cheng DL; Gao ZG; Shi CS; Su MX
Drug Des Devel Ther; 2022; 16():3421-3429. PubMed ID: 36203820
[TBL] [Abstract][Full Text] [Related]
11. Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.
Wang C; Lei K; Jia Y; Jiang Z; Wang S
Exp Ther Med; 2023 Jul; 26(1):324. PubMed ID: 37346410
[TBL] [Abstract][Full Text] [Related]
12. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.
Hua Y; Huang X; Li C; Gao N
Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963
[TBL] [Abstract][Full Text] [Related]
13. Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation.
Liu Y; Chen T; Zhang C; Pan W
Indian J Dermatol; 2023; 68(1):85-90. PubMed ID: 37151267
[TBL] [Abstract][Full Text] [Related]
14. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Ni J; Si X; Wang H; Zhang X; Zhang L
Front Immunol; 2023; 14():1168879. PubMed ID: 37114054
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer.
Zhang D; Kong F; Gao F; Li L; Liang Y; Yu M; Zhao L; Wang N; Jia Y
Heliyon; 2024 Jan; 10(1):e22913. PubMed ID: 38148793
[TBL] [Abstract][Full Text] [Related]
16. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer.
Xu M; Meng X; Lu Y; Wang F
J Gastrointest Oncol; 2022 Apr; 13(2):548-558. PubMed ID: 35557572
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
Xiang J; Gong W; Sun P; Wang X; Liu A
J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
[TBL] [Abstract][Full Text] [Related]
20. Nasal alar metastasis of advanced hepatocellular carcinoma misdiagnosed as reactive cutaneous capillary endothelial proliferation in a patient treated with camrelizumab and apatinib: a case report.
Liu J; Cao G; Zhang G; Liu S; Shi D
J Gastrointest Oncol; 2023 Jun; 14(3):1643-1649. PubMed ID: 37435210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
